Obesity Is Associated With Progression of Atherosclerosis During Statin Treatment

Abstract

Background This study aimed to determine the relationship of statin therapy and cardiovascular risk factors to changes in atherosclerosis in the carotid artery. Methods and Results Carotid magnetic resonance imaging was used to evaluate 106 hyperlipidemic participants at baseline and after 12 months of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor (statin) treatment. Multivariable logistic regression was used to determine factors associated with progression (change in carotid wall volume >0) or regression (change ≤0) of carotid atherosclerosis. Computed tomography coronary calcium scores were obtained at baseline for all participants. The median age was 65 years (interquartile range 60–69 years), and 63% of the participants were male. Body mass index >30, elevated C‐reactive protein, and hypertension were associated with increased carotid wall volume (obesity: odds ratio for progression 4.6, 95% CI 1.8–12.4, P <0.01; C‐reactive protein: odds ratio for progression 2.56, 95% CI 1.17–5.73, P =0.02; hypertension: odds ratio 2.4, 95% CI 1.1–5.3, P <0.05). Higher statin dose was associated with regression of carotid wall volume ( P <0.05). In multivariable analysis, obesity remained associated with progression ( P <0.01), whereas statin use remained associated with regression ( P <0.05). Change in atheroma volume in obese participants was +4.8% versus −4.2% in nonobese participants ( P <0.05) despite greater low‐density lipoprotein cholesterol reduction in obese participants. Conclusions In a population with hyperlipidemia, obese patients showed atheroma progression despite optimized statin therapy. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01212900.